Skip to main content
. Author manuscript; available in PMC: 2021 Nov 10.
Published in final edited form as: J Control Release. 2020 Jul 22;327:100–116. doi: 10.1016/j.jconrel.2020.07.034

Figure 6.

Figure 6.

Effect of EGFR2R-lytic hybrid peptide-TDCA-citric acid complex. (A) Measurement of antitumor effect of complex by monitoring tumor size in mice. The complex demonstrated higher tumor inhibition than cationic peptide and S-1 (5-FU oral formulation, positive control). (B) Tight junction opening effect of the complex in Caco-2 cell monolayers. Reproduced, with permission, from reference [126].